Fabio Turco , Consuelo Buttigliero , Marco Donatello Delcuratolo , Silke Gillessen , Ursula Maria Vogl , Thomas Zilli , Nicola Fossati , Andrea Gallina , Giovanni Farinea , Rosario Francesco Di Stefano , Mariangela Calabrese , Isabella Saporita , Veronica Crespi , Stefano Poletto , Erica Palesandro , Massimo Di Maio , Giorgio Vittorio Scagliotti , Marcello Tucci
{"title":"用于局部和晚期前列腺癌的激素药物：当前使用情况和未来展望。","authors":"Fabio Turco , Consuelo Buttigliero , Marco Donatello Delcuratolo , Silke Gillessen , Ursula Maria Vogl , Thomas Zilli , Nicola Fossati , Andrea Gallina , Giovanni Farinea , Rosario Francesco Di Stefano , Mariangela Calabrese , Isabella Saporita , Veronica Crespi , Stefano Poletto , Erica Palesandro , Massimo Di Maio , Giorgio Vittorio Scagliotti , Marcello Tucci","doi":"10.1016/j.clgc.2024.102138","DOIUrl":null,"url":null,"abstract":"<div><p>Prostate cancer (PC) is generally a hormone-dependent tumor. Androgen deprivation therapy ( has been the standard of care in metastatic disease for more than 80 years. Subsequent studies have highlighted the efficacy of ADT even in earlier disease settings such as in localized disease or in the case of biochemical recurrence (BCR). Improved knowledge of PC biology and ADT resistance mechanisms have led to the development of novel generation androgen receptor pathway inhibitors (ARPI). Initially used only in patients who became resistant to ADT, ARPI have subsequently shown to be effective when used in patients with metastatic hormone-naive disease and in recent years their effectiveness has also been evaluated in localized disease and in case of BCR. The objective of this review is to describe the current role of agents interfering with the androgen receptor in different stages of PC and to point out future perspectives.</p></div>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Hormonal Agents in Localized and Advanced Prostate Cancer: Current Use and Future Perspectives\",\"authors\":\"Fabio Turco , Consuelo Buttigliero , Marco Donatello Delcuratolo , Silke Gillessen , Ursula Maria Vogl , Thomas Zilli , Nicola Fossati , Andrea Gallina , Giovanni Farinea , Rosario Francesco Di Stefano , Mariangela Calabrese , Isabella Saporita , Veronica Crespi , Stefano Poletto , Erica Palesandro , Massimo Di Maio , Giorgio Vittorio Scagliotti , Marcello Tucci\",\"doi\":\"10.1016/j.clgc.2024.102138\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Prostate cancer (PC) is generally a hormone-dependent tumor. Androgen deprivation therapy ( has been the standard of care in metastatic disease for more than 80 years. Subsequent studies have highlighted the efficacy of ADT even in earlier disease settings such as in localized disease or in the case of biochemical recurrence (BCR). Improved knowledge of PC biology and ADT resistance mechanisms have led to the development of novel generation androgen receptor pathway inhibitors (ARPI). Initially used only in patients who became resistant to ADT, ARPI have subsequently shown to be effective when used in patients with metastatic hormone-naive disease and in recent years their effectiveness has also been evaluated in localized disease and in case of BCR. The objective of this review is to describe the current role of agents interfering with the androgen receptor in different stages of PC and to point out future perspectives.</p></div>\",\"PeriodicalId\":2,\"journal\":{\"name\":\"ACS Applied Bio Materials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2024-06-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Applied Bio Materials\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1558767324001095\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MATERIALS SCIENCE, BIOMATERIALS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1558767324001095","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
引用次数: 0
摘要
前列腺癌（PC）通常是一种激素依赖性肿瘤。雄激素剥夺疗法（80 多年来一直是治疗转移性疾病的标准疗法。随后的研究强调了 ADT 的疗效，即使是在早期疾病，如局部疾病或生化复发（BCR）的情况下也是如此。对 PC 生物学和 ADT 耐药机制的进一步了解促进了新一代雄激素受体通路抑制剂 (ARPI) 的开发。ARPI 最初仅用于对 ADT 产生耐药性的患者，但后来在用于转移性激素无依赖性疾病患者时显示出了良好的疗效，近年来还对其在局部疾病和 BCR 患者中的疗效进行了评估。本综述旨在描述干扰雄激素受体的药物目前在 PC 不同阶段的作用，并指出未来的发展前景。
Hormonal Agents in Localized and Advanced Prostate Cancer: Current Use and Future Perspectives
Prostate cancer (PC) is generally a hormone-dependent tumor. Androgen deprivation therapy ( has been the standard of care in metastatic disease for more than 80 years. Subsequent studies have highlighted the efficacy of ADT even in earlier disease settings such as in localized disease or in the case of biochemical recurrence (BCR). Improved knowledge of PC biology and ADT resistance mechanisms have led to the development of novel generation androgen receptor pathway inhibitors (ARPI). Initially used only in patients who became resistant to ADT, ARPI have subsequently shown to be effective when used in patients with metastatic hormone-naive disease and in recent years their effectiveness has also been evaluated in localized disease and in case of BCR. The objective of this review is to describe the current role of agents interfering with the androgen receptor in different stages of PC and to point out future perspectives.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
